EUCTR2014-000305-13-HR进行中（未招募）1 期
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) - MARINER
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12,019
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •The duration of the index hospitalization must have been at least 3 and no more than 10 consecutive days
- •Must meet venous thromboembolism (VTE) risk criteria with a total modified Improve VTE Risk Score of: greater than or equal 4, or 3 with D-dimer > 2*upper limit of normal (ULN), or 2 with D-dimer > 2*ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2700
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5300
排除标准
- •Any serious bleeding within 3 months prior to randomization or occurring during index hospitalization
- •Serious trauma within 4 weeks before randomization
- •History of hemorrhagic stroke at any time in the past
- •Severe head trauma within 3 months of randomization
- •Any medical condition that requires chronic use of any parenteral or oral anticoagulation
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.MedDRA version: 18.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865EUCTR2014-000305-13-DKJanssen-Cilag International NV8,000
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.EUCTR2014-000305-13-PTJanssen-Cilag International NV12,019
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.MedDRA version: 19.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865EUCTR2014-000305-13-DEJanssen-Cilag International NV12,000
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.MedDRA version: 20.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865EUCTR2014-000305-13-LTJanssen-Cilag International NV12,000
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of Rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) in medically ill patients.EUCTR2014-000305-13-GBJanssen-Cilag International NV12,019